The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1490
March 14, 2016
View Complete Issue         Table of Contents 2019 
Isavuconazonium Sulfate (Cresemba) - A New Antifungal
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Isavuconazonium Sulfate (Cresemba) - A New Antifungal
March 14, 2016 (Issue: 1490)
The FDA has approved isavuconazonium sulfate (Cresemba – Astellas) for intravenous and oral treatment of invasive aspergillosis and invasive mucormycosis in adults. Isavuconazonium sulfate is a prodrug of isavuconazole, a broad-spectrum...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Isavuconazonium Sulfate (Cresemba) - A New Antifungal
Article code: 1490d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.